MSH|^~\&|LAB|RCH|||202003191311||ORU^R01|4188209|D|2.3|||AL|NE PID|1||RC00007909|RC7657|LABTEST^GOING^TOTEST||19440615|F||||||||||RC000696/19|9874962522 OBR|1|40736^LAB|00030713^1903:C00010R^LAB^190320:C10^40736|522.2490^BHCG^Beta-HCG^^^21198-7||202003191309|202003191308|||||||202003191308||||||||||LAB|F|||| NTE|1||UCI SCENARIO 4D OBX|1|ST|522.2510^BHCG R^Beta-HCG^^21198-7^21198-7|1|5^^Y|IU/L|<10|N||A^S|F|||202003191311 NTE|1||Reference Intervals, (guideline only) FOR B-HCG (U/L): NTE|2|| NTE|3||Male or non-pregnant female Less than 10 NTE|4||Pregnant female: NTE|5||Time after LMP: Expected beta-HCG range(WHO 3rd IRP): NTE|6||4th week 25 - 426 NTE|7||5th week 25 - 7340 NTE|8||6th week 1080 - 56500 NTE|9||10th week 54100 - 288000 NTE|10||18th week 8910 - 66000 NTE|11||31st week 5310 - 27400 NTE|12||*************************NOTE******************************* NTE|13||Occasional patients with heterophile antibodies may have NTE|14||erroneous BHCG results. Serum BHCG should not be used for NTE|15||routine pregnancy tests. Urine does not contain heterophile NTE|16||antibodies and may be used where apparent discrepant results NTE|17||are experienced. NTE|18||Method:Roche COBAS